The study identified mutations in the rpsL, rrs, and embB genes associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Latvia.

The study identified multiple mutations in genes associated with drug resistance in extensively drug-resistant Mycobacterium tuberculosis isolates from Siberia, including rpoB, katG, rrs, gidB, rpsL, and gyrA.

The study identified mutations in gidB, rpsL, and rrs genes associated with streptomycin resistance in Mycobacterium tuberculosis strains in southern Taiwan.

PhyResSE is a web tool that uses whole-genome sequencing data to identify antibiotic resistance and lineage in Mycobacterium tuberculosis. It accurately detects resistance-associated mutations in genes such as katG, inhA, rpoB, rrs, rpsL, embB, and pncA.

The study identified several AMR genes and mutations in Mycobacterium tuberculosis isolates, including rpoB, katG, inhA, rpsL, rrs, and embB, which confer resistance to rifampicin, isoniazid, streptomycin, and ethambutol. Some mutations, such as I572F in rpoB and D516Y in rpoB, were associated with low-level rifampicin resistance. Additionally, mutations in katG, inhA, rpsL, rrs, and embB were linked to resistance against other first-line anti-TB drugs.

The U1406A mutation in the 16S rRNA gene of Mycobacterium tuberculosis confers resistance to kanamycin and significantly attenuates virulence.

The study identifies the presence of aminoglycoside modifying enzyme genes rrs, aacC2, aacA-aphD, and aphA3 in E. coli isolates from UTI patients in India, indicating a mechanism of resistance to aminoglycoside antibiotics.

The study identified several AMR genes and mutations associated with drug resistance in M. tuberculosis, including rrs, gyrA, inhA, katG, rpoB, embB, pncA, and folC, as well as a novel mutation in Rv2477c linked to kanamycin and amikacin resistance.

The study evaluated the performance of a pyrosequencing assay for detecting drug-resistant tuberculosis, identifying key genes and mutations associated with resistance to isoniazid, rifampicin, fluoroquinolones, and injectable drugs like kanamycin and capreomycin.

The study presents a 10-color assay capable of detecting resistance to isoniazid, fluoroquinolones, amikacin, and kanamycin in Mycobacterium tuberculosis. The assay uses molecular beacons and melting temperature analysis to identify specific mutations in genes such as katG, gyrA, gyrB, rrs, and inhA.

The study presents a comprehensive whole-genome sequencing (WGS) assay for Mycobacterium tuberculosis that enables rapid drug resistance profiling, species identification, and genotyping. The assay successfully identified resistance-associated mutations in genes such as rpoB, katG, inhA, gyrA, gyrB, embB, rrs, rpsL, and pncA, which are linked to resistance against rifampin, isoniazid, ethambutol, streptomycin, and pyrazinamide.

The study identified several AMR genes and mutations in M. tuberculosis, including rrs A1401G, katG S315T, inhA C-15T, rpoB D516Y, gyrA A90V, tlyA insertion, and eis G-10A, which contribute to resistance against various antibiotics such as isoniazid, rifampicin, amikacin, capreomycin, and ofloxacin.

The study identified novel resistance mechanisms in Mycobacterium tuberculosis strains from Southern India, including mutations in katG, fadE24, fabD, gidB, and rrs that contribute to isoniazid and streptomycin resistance.

The study identified mutations in the gyrA gene (A90V, D94G) conferring fluoroquinolone resistance and the rrs gene (A1401G) conferring aminoglycoside resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Saudi Arabia.

The study shows that mutations in gyrB and eis genes improve the detection of second-line drug resistance in Mycobacterium tuberculosis isolates. Specifically, gyrB mutations enhance the detection of ofloxacin resistance, while the eis C-14T mutation improves the detection of kanamycin resistance.

The study evaluated the diagnostic performance of the GenoType MTBDR plus and MTBDR sl assays for detecting drug resistance in Mycobacterium tuberculosis isolates. Key findings include the identification of specific mutations in rpoB, katG, inhA, gyrA, rrs, and embB genes associated with resistance to rifampicin, isoniazid, ofloxacin, kanamycin, and ethambutol.

The study identified mutations in the gyrA and rrs genes associated with resistance to fluoroquinolones and aminoglycosides/cyclopeptides in Mycobacterium tuberculosis isolates from India.

The study identifies several AMR genes and mutations in Mycobacterium africanum Lineage 5, including rpoB, katG, inhA, pncA, embB, rrs, and eis, which are associated with resistance to rifampicin, isoniazid, pyrazinamide, ethambutol, and kanamycin. Additionally, a 33.8 kb deletion in the katG gene was found to confer isoniazid resistance.

The study identified mutations in the erm(41), rrl, and rrs genes associated with clarithromycin and amikacin resistance in Mycobacterium abscessus isolates from Northeast Thailand.

The study presents rule-based classifiers that accurately predict antimicrobial resistance using genome sequences, identifying known resistance mechanisms such as mutations in rrs for kanamycin resistance and genes like blaKPC-2, bleMBL, and blaNDM-1 for meropenem resistance.

The study identified specific mutations in genes such as katG, rpoB, embB, rrs, and rpsL that confer resistance to isoniazid, rifampicin, ethambutol, and streptomycin in Mycobacterium tuberculosis isolates from Egypt and Saudi Arabia.

The paper discusses the identification of drug resistance determinants in Mycobacterium tuberculosis using whole-genome sequencing, highlighting the importance of mutations in genes such as rpoB, katG, inhA, pncA, embCAB, gyrA, gyrB, atpE, rrs, rpsL, ald, ethA, and thyX. It also identifies new resistance-associated mutations in ethA and the thyX promoter.

The study identified various AMR genes and mutations in drug-resistant Mycobacterium tuberculosis isolates from North West Pakistan, including katG, rpoB, embB, gyrA, rrs, and pncA, which are associated with resistance to isoniazid, rifampicin, ethambutol, fluoroquinolones, aminoglycosides, and pyrazinamide, respectively.

The paper discusses various AMR genes and mutations in Mycobacterium abscessus, including erm(41) for macrolide resistance, aac(2')-Ib for aminoglycoside resistance, blaMab for beta-lactam resistance, mabTetX for tetracycline resistance, rrs and rpsL for aminoglycoside resistance, mmpL3 for capuramycin resistance, and whiB7 for regulating resistance to aminoglycosides and macrolides.

The study identified mutations in genes such as rpoB, katG, inhA, pncA, embB, rpsL, and rrs that confer resistance to rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin in multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates in Kuwait. These findings highlight the molecular mechanisms underlying drug resistance and provide insights into local transmission of MDR-TB.

The study identifies multiple AMR genes and mutations associated with ethionamide, streptomycin, isoniazid, ethambutol, pyrazinamide, rifampicin, fluoroquinolones, terizidone, cycloserine, bedaquiline, and clofazimine resistance in Mycobacterium tuberculosis strains.

The study identifies several genes and mutations associated with drug resistance in Mycobacterium tuberculosis, including katG, inhA, rpoB, embB, pncA, rpsL, rrs, gyrA, thyA, and folC, which are linked to resistance against isoniazid, ethambutol, rifampicin, streptomycin, aminoglycosides, fluoroquinolones, and para-aminosalicylic acid.

The study introduces ECAT, a novel method that leverages homoplasy to improve the detection of antibiotic resistance mutations in bacterial genomes. It successfully identifies known resistance mutations and detects secondary genes associated with resistance, such as rpoC for rifampicin resistance.

The study identifies various AMR genes and mutations in MDR-TB patients, highlighting the significance of pncA gene mutations in predicting poor treatment outcomes and their association with resistance to pyrazinamide, as well as other genes like rpoB, katG, inhA, gyrA, and others linked to resistance against rifampin, isoniazid, and fluoroquinolones.

The study identifies the rrs gene with a g1379t point mutation as responsible for spectinomycin resistance in Mycobacterium tuberculosis. Additionally, the rv1258c gene's inactivation increases susceptibility to SPT, and the fusA1 gene's c1384t mutation reduces susceptibility to fusidic acid.

The study identifies several mutations in Mycobacterium tuberculosis that confer resistance to various antibiotics, including isoniazid, rifampicin, streptomycin, fluoroquinolones, pyrazinamide, ethionamide, bedaquiline, clofazimine, and kanamycin. These mutations were found to evolve over five years of treatment in a patient with inadequate compliance.

The paper reviews the molecular mechanisms of resistance in Mycobacterium abscessus complex (MABC), highlighting the roles of erm(41), rrs, Bla_Mab, and MabTetX genes in conferring resistance to macrolides, aminoglycosides, beta-lactams, and tetracyclines respectively.

The study identified various AMR genes and mutations in rapidly growing mycobacteria, including erm(41), rrl, rrs, and gyrA, which are associated with resistance to macrolides, aminoglycosides, and fluoroquinolones. The T28C mutation in erm(41) was linked to loss of macrolide resistance, while mutations in rrl and gyrA were associated with acquired resistance to macrolides and fluoroquinolones, respectively.

The study evaluates the performance of the GeneLEAD VIII and Deeplex Myc-TB assay for detecting drug resistance in Mycobacterium tuberculosis complex. It identifies several AMR genes and mutations associated with resistance to various antituberculous drugs.

The study identified several antibiotic resistance genes (ARGs) associated with tuberculosis treatment in wastewater samples from South Africa, including rrs (streptomycin resistance), pncA (pyrazinamide resistance), katG (isoniazid resistance), rpoB (rifampicin resistance), embB (ethambutol resistance), gyrA (ofloxacin resistance), gyrB (moxifloxacin resistance), atpE (bedaquiline resistance), ethR (ethionamide resistance), and eis (kanamycin/amikacin resistance).

The study evaluated the GenoType MTBDRsl assay for detecting resistance to ofloxacin, kanamycin, and ethambutol in MDR-TB patients in Bangladesh. Key findings include the identification of specific mutations in gyrA, rrs, and embB genes associated with resistance to these drugs.

The study evaluates the accuracy of a nanopore sequencing approach for detecting drug-resistance-associated variants in Mycobacterium tuberculosis, demonstrating high agreement with Illumina sequencing for known resistance variants and phylogenetic markers.

The study identified mutations in genes such as rpoB, katG, embB, pncA, rrs, fabG1, and gyrA that confer resistance to rifampicin, isoniazid, ethambutol, pyrazinamide, streptomycin, aminoglycosides, ethionamide, and fluoroquinolones in MDR and XDR-TB isolates in Slovakia.

The study experimentally confirms that the g878a mutation in the rrs gene of Mycobacterium tuberculosis confers low-level resistance to streptomycin.

The study identified several mutations in the rrs, eis, whiB7, tlyA, and gyrA genes associated with resistance to kanamycin, capreomycin, and ofloxacin in Mycobacterium tuberculosis clinical isolates from western and northern India.

The study characterized various AMR genes and mutations in fluoroquinolone-resistant and multidrug-resistant Mycobacterium tuberculosis isolates using whole-genome sequencing, identifying key resistance mechanisms for several antibiotics.

The study identifies various AMR genes and mutations in Mycobacterium tuberculosis isolates from HIV-positive and HIV-negative patients in Russia, highlighting the association of specific mutations with resistance to ethambutol, isoniazid, rifampicin, kanamycin, amikacin, and capreomycin.

The study identifies mutations in rrl, erm(41), and rrs genes associated with clarithromycin and amikacin resistance in Mycobacterium abscessus complex. These mutations were validated through melting curve analysis and phenotypic susceptibility testing.

The study identifies various AMR genes and mutations in Mycobacterium tuberculosis complex isolates, including rpoB, fabG1, inhA, ndh, katG, mshA, ahpC, gyrA, gyrB, rrs, eis, embCAB, pncA, and rpsA, which are associated with resistance to rifampicin, isoniazid, fluoroquinolones, aminoglycosides, ethambutol, and pyrazinamide.

The study identified the presence of the erm(41) gene associated with inducible macrolide resistance in M. abscessus subsp. abscessus and the MUT2 mutation in the rrl gene linked to constitutive resistance in M. abscessus subsp. massiliense.

The study demonstrated the effectiveness of MGIT-seq for identifying nontuberculous mycobacteria (NTM) and predicting drug resistance, particularly for macrolides and amikacin. Key findings include the identification of specific mutations in rrl, erm (41), and rrs genes associated with resistance.

The study identifies genomic rearrangements in the porin locus and mutations in the 23S rRNA gene (rrl) in Mycobacterium abscessus subspecies massiliense isolates from CF patients, leading to reduced porin expression and macrolide resistance.

The study identifies rrs A1401G as the predominant mutation in aminoglycoside-resistant Mtb isolates from Guangdong, demonstrating its significant role in conferring resistance to amikacin and kanamycin through experimental validation.

The study presents a targeted next-generation sequencing (tNGS) assay for detecting drug-resistant Mycobacterium tuberculosis directly from clinical specimens, demonstrating high concordance with whole genome sequencing (WGS) results and significantly reducing turnaround time compared to traditional methods.

The study identified mutations in erm (41), rrl, and rrs genes associated with clarithromycin and amikacin resistance in Mycobacterium abscessus complex isolates.

The study identified various AMR genes and mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Latvia, highlighting discrepancies between phenotypic and genotypic DST results for certain drugs.

The study identified various AMR genes and mutations in M. tuberculosis isolates, including katG, inhA, fabG, rpsL, rrs, pncA, embB, and gyrA, which are associated with resistance to isoniazid, streptomycin, pyrazinamide, ethambutol, and fluoroquinolones. The study also highlighted the limitations of phenotypic drug susceptibility testing and the potential of WGS in identifying resistance mechanisms.

The study identifies numerous genetic mutations associated with resistance to various antibiotics in Mycobacterium tuberculosis, including rifampicin, isoniazid, ethambutol, fluoroquinolones, and linezolid. These findings enhance the understanding of AMR mechanisms and support the development of more accurate diagnostics and treatment strategies.

The study identified erm(41)T28 gene mutations associated with macrolide resistance in Mycobacterium abscessus subsp. abscessus. Additionally, rrl and rrs gene mutations were found to confer resistance to macrolides and aminoglycosides respectively.

The study identifies numerous genetic determinants of resistance and susceptibility in Mycobacterium tuberculosis, including mutations in genes such as katG, rpoB, inhA, fabG1, embA, embB, gyrA, gyrB, rrs, and eis, which are associated with resistance to various antibiotics.

The study identified mutations in the rrs gene, particularly rrs A1401G, as the primary cause of resistance to second-line injectable drugs (SLIDs) kanamycin and amikacin in multidrug-resistant tuberculosis (MDR-TB) isolates.

The study developed a deep amplicon sequencing (DAS) panel targeting 941 drug-resistant mutations (DRMs) in 47 genes associated with 20 anti-tuberculosis drugs. The panel demonstrated high accuracy in detecting drug resistance, with results comparable to those of whole-genome sequencing (WGS) and phenotypic drug susceptibility testing (pDST).

The study developed a novel PCR/MALDI-TOF MS platform for the identification of mycobacteria and detection of genetic markers of resistance, including erm(41), rrl, and rrs mutations associated with macrolide and aminoglycoside resistance.

The study identifies several genes associated with antibiotic resistance in Mycobacterium tuberculosis, including rpoB, embB, katG, rpsL, gyrA, rrs, rplC, and PPE54, which are linked to resistance against various antibiotics such as rifampicin, ethambutol, isoniazid, fluoroquinolones, aminoglycosides, and linezolid.

The study identified resistance mechanisms in Mycobacterium abscessus isolates from cystic fibrosis patients, including inducible resistance to clarithromycin mediated by erm(41) mutations, acquired resistance to clarithromycin via rrl gene mutations, and amikacin resistance associated with rrs gene mutations.

The study identified several resistance-associated genes and mutations in Mycobacterium tuberculosis using nanopore sequencing, including rpoB (Rifampicin resistance), katG (Isoniazid resistance), embB (Ethambutol resistance), rpsL (Streptomycin resistance), gyrA (Fluoroquinolones resistance), and rrs (Amikacin, Kanamycin, Capreomycin resistance).

The study introduces LLMTB, a large language model that predicts antibiotic resistance in Mycobacterium tuberculosis by analyzing genomic data. It identifies key resistance genes and intergenic regions associated with various antibiotics, demonstrating superior performance compared to existing methods.

The study evaluated the performance of MassARRAY technology for detecting Mycobacterium tuberculosis and identifying drug resistance, focusing on mutations in rpoB, katG, embB, rrs, rpsL, and gyrA associated with resistance to rifampicin, isoniazid, ethambutol, amikacin, streptomycin, and fluoroquinolones.

The mlstverse system accurately identifies Mycobacterium abscessus subspecies and predicts drug resistance to clarithromycin and amikacin based on genetic analysis.

The study demonstrates the effectiveness of CapSeq in detecting and genotyping bacterial pathogens and antibiotic resistance genes in bovine respiratory disease (BRD) samples, highlighting the presence of various resistance genes such as bla-TEM, bla-ROB, tetM, tetQ, tetS, tetH, tetX, floR, rrs, and rrl.

The study identifies multiple resistance mutations in XDR Mycobacterium tuberculosis isolates from Argentina, including katG Ser315Thr, fabG1 -15C > T, rpoB Ser450Leu and Asp435Val, embB Gly406Ala and Met306Ile, pncA Gly10Pro and Arg154Gly, rrs 1401A > G, and gyrA mutations associated with fluoroquinolone resistance.

The study identified several mutations in genes associated with drug resistance in Mycobacterium tuberculosis isolates from Meigu County, Sichuan Province, China. These include mutations in rpoB, katG, inhA, gyrA, rpsL, rrs, embB, and pncA, which confer resistance to rifampicin, isoniazid, fluoroquinolones, streptomycin, aminoglycosides, ethambutol, and pyrazinamide, respectively.

The study identifies mutations in the rpsL gene and 16S rRNA (rrs) that confer streptomycin resistance in Mycobacterium tuberculosis.

The paper discusses the identification of genes and mutations associated with drug resistance in Mycobacterium tuberculosis, focusing on isoniazid, rifampin, streptomycin, ethambutol, and fluoroquinolones.